NCT04731467已完成1 期
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 18
- 主要终点
- Part A: Incidence of treatment emergent adverse events
研究概览
简要总结
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Parts A and C are non-randomized parts, part D is a randomized part.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part A: Previously treated subjects with recurrent and/or metastatic NSCLC, pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma with documented progression/intolerance following at least one previous therapy (and not more than 2 previous regimens); Part C: Subjects with histologically confirmed advanced metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded; subjects with a maximum of 1 prior treatment regimen for metastatic disease excluding: nab-paclitaxel containing regimens and up to 8 weeks from last chemotherapy treatment (Arm #1); fluoropyrimidine or irinotecan containing regimens and up to 8 weeks from last chemotherapy treatment (Arm #2).
- •Part C, D: Subjects with histologically confirmed advanced metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded.
- •Parts C, D: Subjects who have progressed on or after standard of care chemotherapy with a maximum of 1 prior treatment regimen for advanced metastatic disease:
- •Subjects enrolled in arm with gemcitabine/nab-paclitaxel combination should have received a fluoropyrimidine and/or irinotecan containing regimen in the first line of treatment; Prior gemcitabine containing regimen may be allowed only if completed at least 6 months prior to study enrollment.
- •Arm #2: Subjects enrolled in arm with Nal-IRI/5FU/LV combination should have received a gemcitabine and/or nab-paclitaxel containing regimen in the first line of treatment; Prior irinotecan and/or fluoropyrimidine containing regimens may be allowed only if completed at least 6 months prior to study enrollment.
- •Part A: Availability of an archival tumor sample prior to first treatment. Parts C, D: Fresh tumor biopsy must be obtained within 3 months prior to enrollment and after the last systemic treatment was completed.
- •Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors since last antitumor therapy;
- •ECOG performance status score of 0 or 1;
- •Adequate safety lab results;
- •Stable brain metastases;
- •WCBP (Women of Childbearing Potential) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test, WCBP must agree to abstain from sex or use an adequate method of contraception, males must abstain from sex with WCBP or use an adequate method of contraception.
排除标准
- •Part A: Received more than two prior systemic regimens for the metastatic disease Parts C and D: Received more than 1 prior systemic regimens for the advanced metastatic disease
- •Part A: History of weight loss >10% over the 2 months prior to Screening;
- •Unresolved AEs > Grade 1 from prior anticancer therapy.
- •Concurrent malignancy requiring treatment;
- •Active, untreated central nervous system (CNS) metastases;
- •Subjects previously treated with an anti PD-1/PD-L1 targeting agent with history immune mediated toxicity;
- •Severely immunocompromised;
- •History of allergy or hypersensitivity to any of the study treatment components;
- •Major surgery within 4 weeks of study administration;
- •Received a live / attenuated vaccine within 30 days of first treatment
- •Clinically relevant serious co-morbid medical conditions including, but not limited to:
- •Active infection;
- •Recent (within six months of Screening) cardiac disease, myocardial infarction, or severe or unstable angina;
- •History of serious arrhythmia;
- •Chronic obstructive or chronic restrictive pulmonary disease, pulmonary hypertension history of or active interstitial lung disease or pneumonitis;
- •Prior organ allograft;
- •Subjects with active, known or suspected autoimmune disease;
- •History of active or latent tuberculosis infection;
- •Positive test for HIV, HBV, or HCV;
- •Radiation within two weeks prior to the first study treatment;
- •Treatment with another investigational therapy within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;
- •Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to treatment;
- •Pregnant or lactating women.
研究组 & 干预措施
Part A- Dose escalation of CM24 in combination with nivolumab
Experimental
干预措施: CM-24 and Nivolumab - Dose Escalation (Drug)
Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Experimental
干预措施: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion (Drug)
Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Experimental
干预措施: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion (Drug)
Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Experimental
干预措施: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion (Drug)
Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Experimental
干预措施: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion (Drug)
Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine
Active Comparator
干预措施: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion (Drug)
Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV
Active Comparator
干预措施: Nivolumab and Nal-IRI/5-FU/LV - Expansion (Drug)
结局指标
主要结局
Part A: Incidence of treatment emergent adverse events
时间窗: Up to 24 months
Incidence of treatment emergent adverse events with CM-24 and nivolumab in adults with selected recurrent or metastatic solid tumors
Part D: Overall survival
时间窗: Up to 24 months
This is an exploratory randomized sub-study with the objective of estimating the efficacy of CM24 and nivolumab with chemotherapy (Nal-IRI/5-FU/LV or gemcitabine/ nab-paclitaxel) and chemotherapy only (Nal- IRI/5-FU/LV or gemcitabine/nab-paclitaxel) as measured by overall survival.
Part C: Safety and tolerability
时间窗: Up to 24 months
Incidence of treatment emergent adverse events with CM-24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV in adults with advanced metastatic pancreatic cancer
次要结局
- Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the average area under the concentration curve [AUC](Up to 24 months)
- Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the median area under the concentration curve [AUC](Up to 24 months)
- Disease Control Rate when CM24 is used in combination with nivolumab(Up to 24 months)
- Overall Survival when CM24 is used in combination with nivolumab(Up to 48 months)
- Population pharmacokinetics when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV as measured by the median area under the concentration curve [AUC](Up to 24 months)
- Disease Control Rate when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV(Up to 24 months)
- Progression Free Survival when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV(Up to 48 months)
- Median Duration of Response when CM24 is used in combination with nivolumab(Up to 24 months)
- Median Time to Response when CM24 is used in combination with nivolumab(Up to 24 months)
- Area under the serum concentration curve [AUC](Up to 24 months)
- Drug clearance(Up to 24 months)
- Progression Free Survival when CM24 is used in combination with nivolumab(Up to 48 months)
- Population pharmacokinetics when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV as measured by the maximum plasma concentration [Cmax](Up to 24 months)
- Half life(Up to 24 months)
- Serum ADA parameters(Up to 24 months)
- Time to Response when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV(Up to 24 months)
- Maximum serum concentration [Cmax](Up to 24 months)
- Time of maximum concentration [Tmax](Up to 24 months)
- Volume of distribution(Up to 24 months)
- Objective Response Rate when CM24 is used in combination with nivolumab(Up to 24 months)
- Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the maximum plasma concentration [Cmax](Up to 24 months)
- Population pharmacokinetics when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV as measured by the average area under the concentration curve [AUC](Up to 24 months)
- Duration of Response when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV(Up to 24 months)
- Overall Survival when CM24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV(Up to 48 months)
研究者
研究点 (18)
Loading locations...
相似试验
招募中
1 期
A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisMyelofibrosisNCT04176198Sumitomo Pharma America, Inc.240
招募中
1 期
A Beta-only IL-2 ImmunoTherapY StudyBasal Cell CarcinomaClear Cell Renal Cell CarcinomaMerkel Cell CarcinomaPleural MesotheliomaCutaneous MelanomaSkin CancerMucosal MelanomaOvarian CancerGastric CancerCervical CancerBladder CancerEsophageal CancerNCT05086692Medicenna Therapeutics, Inc.115
尚未招募
1 期
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesMultiple MyelomaLymphomaAcute Myeloid LeukemiaNCT05055791CSPC ZhongQi Pharmaceutical Technology Co., Ltd.312
已完成
1 期
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03446417Zeno Pharmaceuticals, Inc.34
已完成
1 期
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.Endometrial NeoplasmsSolid TumorHead and Neck CancerOvarian CancerNCT04570839Compugen Ltd48